Analyst Ratings For Alpine Immune Sciences Inc (NASDAQ:ALPN)
Today, Piper Jaffray Companies initiated coverage on Alpine Immune Sciences Inc (NASDAQ:ALPN) with a Overweight.
There are 5 Buy Ratings, no Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock.
The current consensus rating on Alpine Immune Sciences Inc (NASDAQ:ALPN) is Buy with a consensus target price of $13.00 per share, a potential 104.72% upside.
Some recent analyst ratings include
- 9/27/2018-Alpine Immune Sciences Inc (NASDAQ:ALPN) has coverage initiated with a Overweight rating
- 8/13/2018-Alpine Immune Sciences Inc (NASDAQ:ALPN) has coverage initiated with a Buy rating and $13.00 price target
- 6/29/2018-Alpine Immune Sciences Inc (NASDAQ:ALPN) has coverage initiated with a Outperform rating and $13.00 price target
- 6/28/2018-Alpine Immune Sciences Inc (NASDAQ:ALPN) has coverage initiated with a Outperform rating and $13.00 price target
- 5/17/2018-Alpine Immune Sciences Inc (NASDAQ:ALPN) has coverage initiated with a Outperform rating and $13.00 price target
- 7/27/2017-Alpine Immune Sciences Inc (NASDAQ:ALPN) has coverage initiated with a Buy ➝ Buy rating and $17.00 price target
- 4/19/2017-Alpine Immune Sciences Inc (NASDAQ:ALPN) had its Hold rating reiterated by Cowen
Recent Insider Trading Activity For Alpine Immune Sciences Inc (NASDAQ:ALPN)
Alpine Immune Sciences Inc (NASDAQ:ALPN) has insider ownership of 69.00% and institutional ownership of 56.87%.
- On 6/20/2017 Value Fund L P Biotechnology, Insider, bought 17,806 with an average share price of $2.25 per share and the total transaction amounting to $40,063.50.
- On 6/7/2017 Bvf Partners L P/Il, Major Shareholder, bought 36,900 with an average share price of $2.28 per share and the total transaction amounting to $84,132.00.
- On 6/7/2017 Value Fund L P Biotechnology, Insider, bought 72,650 with an average share price of $2.29 per share and the total transaction amounting to $166,368.50.
- On 6/5/2017 Bvf Partners L P/Il, Major Shareholder, bought 35,750 with an average share price of $2.29 per share and the total transaction amounting to $81,867.50.
- On 5/31/2017 Value Fund L P Biotechnology, Insider, bought 47,000 with an average share price of $2.27 per share and the total transaction amounting to $106,690.00.
- On 5/19/2017 Value Fund L P Biotechnology, Insider, bought 78,858 with an average share price of $2.30 per share and the total transaction amounting to $181,373.40.
- On 5/11/2017 Value Fund L P Biotechnology, Insider, bought 109,034 with an average share price of $2.32 per share and the total transaction amounting to $252,958.88.
About Alpine Immune Sciences Inc (NASDAQ:ALPN)
Alpine Immune Sciences, Inc. focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, inflammatory disorders, and other diseases. Its lead programs include ALPN-101, an ICOS/CD28 antagonist program for the treatment of autoimmune and inflammatory diseases; and ALPN-202 program for the treatment of cancer. The company has a collaboration and licensing agreement with the Kite Pharma, Inc. for discovering and developing protein-based immunotherapies targeting the immune synapse to treat cancer. Alpine Immune Sciences, Inc. is headquartered in Seattle, Washington.
Recent Trading Activity for Alpine Immune Sciences Inc (NASDAQ:ALPN)
Shares of Alpine Immune Sciences Inc closed the previous trading session at 6.35 −0.15 2.31% with 5000 shares trading hands.